21 CFR § 520.1705 - Pergolide.

---
identifier: "/us/cfr/t21/s520.1705"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 520.1705 - Pergolide."
title_number: 21
title_name: "Food and Drugs"
section_number: "520.1705"
section_name: "Pergolide."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "E"
subchapter_name: "ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS"
part_number: "520"
part_name: "ORAL DOSAGE FORM NEW ANIMAL DRUGS"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 360b."
regulatory_source: "40 FR 13838, Mar. 27, 1975, unless otherwise noted."
cfr_part: "520"
---


# 520.1705 Pergolide.

(a) *Specifications.* Each tablet contains 1 milligram (mg) peroglide (as pergolide mesylate).

(b) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.

(c) *Conditions of use in horses*—(1) *Amount.* Administer orally at a starting dose of 2 micrograms/kilograms (µ/kg) once daily. Dosage may be adjusted to effect, not to exceed 4 µg/kg daily.

(2) *Indications for use.* For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease).

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[77 FR 15960, Mar. 19, 2012, as amended at 81 FR 22523, Apr. 18, 2016]